Literature DB >> 16335923

N-picolyl derivatives of Kemp's triamine as potential antitumor agents: a preliminary investigation.

Celeste Aida S Regino1, Suzy V Torti, Rong Ma, Glenn P A Yap, Kevin A Kreisel, Frank M Torti, Roy P Planalp, Martin W Brechbiel.   

Abstract

Preorganized tripodal ligands such as the N-picolyl derivatives of cis,cis-1,3,5-triamino-cis,cis-1,3,5-trimethylcyclohexane (Kemp's triamine) were prepared as analogues to N,N',N''-tris(2-pyridylmethyl)-cis,cis-1,3,5-triaminocyclohexane (tachpyr) in hopes of enhancing the rate of formation and stability of the metal complexes. A tricyclic bisaminal was formed via the reduction of the Schiff base, while the tri(picolyl) derivative was synthesized via reductive amination of pyridine carboxaldehyde. Their cytotoxicities to the HeLa cell line were evaluated and directly compared to tachpyr and N,N',N''-tris(2-pyridylmethyl)tris(2-aminoethyl)amine (trenpyr). Results indicate that N,N',N''-tris(2-pyridylmethyl)-cis,cis-1,3,5-triamino-cis,cis-1,3,5-trimethylcyclohexane (Kemp's pyr) exhibits cytotoxic activity against the HeLa cancer cell line comparable to tachpyr (IC50 approximately 8.0 microM). Both Kemp's pyr and tachpyr show higher cytotoxic activity over the aliphatic analogue of trenpyr (IC50 approximately 14 microM), suggesting that the major contributor to the activity is the ligand's ability to form a stable and tight complex and that the equatorial/axial equilibrium impacting the complex formation for the cyclohexane-based ligands is not significant.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16335923      PMCID: PMC2597376          DOI: 10.1021/jm050724r

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  26 in total

1.  Tricationic Metal Complexes ([ML][NO(3)](3), M = Ga, In) of N,N',N"-Tris(2-pyridylmethyl)- cis-1,3,5-triaminocyclohexane: Preparation and Structure.

Authors:  Kerry A. Hilfiker; Martin W. Brechbiel; Robin D. Rogers; Roy P. Planalp
Journal:  Inorg Chem       Date:  1997-09-24       Impact factor: 5.165

2.  p53-independent apoptosis mediated by tachpyridine, an anti-cancer iron chelator.

Authors:  R D Abeysinghe; B T Greene; R Haynes; M C Willingham; J Turner; R P Planalp; M W Brechbiel; F M Torti; S V Torti
Journal:  Carcinogenesis       Date:  2001-10       Impact factor: 4.944

3.  Deferoxamine, cyclophosphamide, etoposide, carboplatin, and thiotepa (D-CECaT): a new cytoreductive chelation-chemotherapy regimen in patients with advanced neuroblastoma.

Authors:  A Donfrancesco; G Deb; C Dominici; A Angioni; M Caniglia; L De Sio; P Fidani; A Amici; L Helson
Journal:  Am J Clin Oncol       Date:  1992-08       Impact factor: 2.339

4.  Deferoxamine inhibition of human neuroblastoma viability and proliferation.

Authors:  D L Becton; P Bryles
Journal:  Cancer Res       Date:  1988-12-15       Impact factor: 12.701

5.  Effect of iron deficiency and desferrioxamine on DNA synthesis in human cells.

Authors:  A V Hoffbrand; K Ganeshaguru; J W Hooton; M H Tattersall
Journal:  Br J Haematol       Date:  1976-08       Impact factor: 6.998

Review 6.  Analogues of pyridoxal isonicotinoyl hydrazone (PIH) as potential iron chelators for the treatment of neoplasia.

Authors:  D R Richardson
Journal:  Leuk Lymphoma       Date:  1998-09

7.  A 1,3,5-triaxial triaminocyclohexane: the triamine corresponding to Kemp's triacid.

Authors:  Fredric M Menger; Jianwei Bian; Vladimir A Azov
Journal:  Angew Chem Int Ed Engl       Date:  2002-07-15       Impact factor: 15.336

8.  Tumor cell cytotoxicity of a novel metal chelator.

Authors:  S V Torti; F M Torti; S P Whitman; M W Brechbiel; G Park; R P Planalp
Journal:  Blood       Date:  1998-08-15       Impact factor: 22.113

9.  Effects of a single course of deferoxamine in neuroblastoma patients.

Authors:  A Donfrancesco; G Deb; C Dominici; D Pileggi; M A Castello; L Helson
Journal:  Cancer Res       Date:  1990-08-15       Impact factor: 12.701

10.  Iron nutrition and tumor growth: decreased tumor growth in iron-deficient mice.

Authors:  H W Hann; M W Stahlhut; B S Blumberg
Journal:  Cancer Res       Date:  1988-08-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.